Benitec Biopharma FY2024 net loss $22.4M, cash $50.9M; BB-301 shows swallowing improvement

Benitec Biopharma Inc.

Net loss of $22.4M ($5.51 per share) for FY2024; cash and equivalents $50.9M as of June 30, 2024.
Oversubscribed $40M PIPE closed April 2024; cash runway extended through 2025.
Interim data for first low-dose BB-301 subject showed clinically meaningful improvements in swallowing at 90 and 180 days; no SAEs.
Second subject dosed Feb 2024; third subject expected Q4 2024.
Kishen Mehta appointed to board effective June 26, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.